Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)

Hyttel, J. · 1994 · International Clinical Psychopharmacology

Abstract

Established antidepressants including tricyclic antidepressants (TCAs), tetracyclic antidepressants and monoamine oxidase inhibitors (MAOIs) affect a series of neurotransmitter functions. In the debate of clinical efficacy much attention has focused on the uptake of noradrenaline (NA) and serotonin (5-HT) as a means to increase neuronal activity. Most antidepressants, whether classic or new, inhibit the uptake of either one or the other or both transmitters. Besides that, all of the classical antidepressants potently inhibit a series of neurotransmitter receptors. A series of newer antidepressants preferentially increase 5-HT transmission by inhibiting 5-HT uptake. Selective serotonin reuptake inhibitors (SSRIs) are those which preferably inhibit 5-HT uptake compared with NA, and which at the same time have no or only slight effect on other uptake mechanisms, neurotransmitter receptors, enzymes, etc. Five SSRIs are currently marketed, i.e. citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. They all fulfil the above-mentioned criteria. Citalopram is the most selective 5-HT-uptake inhibitor, whereas paroxetine is the most potent. By and large the rank order of selectivity is equal in in vitro studies, in biochemical in vivo studies and in behavioural studies. Selectivity and potency for 5-HT uptake do not coincide. The selectivity of SSRIs is also founded on the lack of inhibition of receptors for different neurotransmitters, e.g. acetylcholine, histamine, NA, 5-HT or dopamine (DA), as well as monoamine oxidase (MAO). Citalopram, fluoxetine and sertraline are metabolized to compounds possessing similar properties as the parent drugs, whereas this is not the case with the metabolites of fluvoxamine and paroxetine. Upon repeated administration SSRIs maintain the selective and potent inhibition of 5-HT uptake. Although repeated treatment with TCAs and electroconvulsive shocks leads to changes in receptor number and pharmacological responsiveness, e.g. down-regulation of β-adrenoceptors and down-regulation of 5-HT2A -mediated function, no consistent changes are seen after prolonged treatment with SSRIs. Since the marketed SSRIs all show clear antidepressant effect, this receptor regulation seems not to be a prerequisite for clinical antidepressant activity.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-199403001-00004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Cited by

See all 502

Metadata

Authors
Hyttel, J.
Affiliations
Lundbeck (Denmark) (DK)
Corresponding author
Hyttel, J.
Venue
International Clinical Psychopharmacology
Published
1994-03
Volume
9
Pages
19-26
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2076639163
Cited by
492
References
1
Citations by year
2026: 3 · 2025: 8 · 2024: 7 · 2023: 4 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 9 · 2018: 4 · 2017: 4 · 2016: 11 · 2015: 8 · 2014: 8 · 2013: 7 · 2012: 11
FWCI
17.94
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
selective serotonin reuptake inhibitors, serotonin uptake inhibition, norepinephrine uptake, antidepressant mechanism, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, drug metabolism, receptor down-regulation, tricyclic antidepressants, electroconvulsive therapy
MeSH terms
Animals, Brain, Depressive Disorder, Humans, Synaptic Transmission, Receptors, Serotonin, Structure-Activity Relationship, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). https://app.cochat.ai/papers/10.1097/00004850-199403001-00004
The paper
Hyttel, J. (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199403001-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.